BTK and B-cell chronic lymphocytic leukemia: These studies confirmed that acalabrutinib has a high ORR in both treatment naïve and relapsed CLL patients, as the efficacy observed in our analysis might be explained through the mechanism of action of acalabrutinib as a selective BTK inhibitor.